Xellia is a fully integrated specialty company, providing pharma customers with APIs, injectable FDFs and recently, products based on proprietary infusion delivery (ready-to-use, RTU) and aqueous droplet inhalation (ADI) technologies. Several of the company’s anti-infectives are indispensable in critical-care practice – and for whom Xellia are the world’s dominant supplier.

They are also the world-leading supplier of Vancomycin and Colistimethate Sodium (CMS). The range of anti-infective treatments combat most types of bacterial and antibiotic-resistant infections and certain fungal diseases.

As one of the leading API and FDFs companies in the world, Xellia has manufacturing facilities in Norway, Denmark, Hungary and China. The majority shareholder of Xellia is Novo AS.